Intelligence Feed event · Equity · 2026-09-03

    Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45M

    Question

    Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45M

    Direct answer

    Fortrea has expanded its Phase 1 research capabilities by acquiring the Early Phase Services unit of Worldwide Clinical Trials for $45 million in cash. The asset package includes high-throughput bioanalytical laboratory space in Austin and specialized inpatient clinical beds in San Antonio.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45M”, revision 1, evidence through 2026-09-03. https://marketontology.com/market-events/2026-09-03/fortrea-acquires-worldwide-clinical-trials-early-phase-unit-for-45m-ce4e75

    EQUITY
    Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45M
    Fortrea has expanded its Phase 1 research capabilities by acquiring the Early Phase Services unit of Worldwide Clinical Trials for $45 million in cash. The asset package includes high-throughput bioanalytical laboratory space in Austin and specialized inpatient clinical beds in San Antonio.
    FTRE
    Impact
    66
    SEP 3
    SIG
    85%
    FTRE
    Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45M
    Fortrea has expanded its Phase 1 research capabilities by acquiring the Early Phase Services unit of Worldwide Clinical Trials for $45 million in cash. The asset package includes high-throughput bioanalytical laboratory space in Austin and specialized inpatient clinical beds in San Antonio.
    → Acquiring early-phase bioanalytical capacity directly increases FTRE high-margin trial capacity and specialized pharmacology service revenue.
    Impact
    Fortrea has expanded its Phase 1 research capabilities by acquiring the Early Phase Services unit of Worldwide Clinical Trials for $45 million in cash. The asset package includes high-throughput bioanalytical laboratory space in Austin and specialized inpatient clinical beds in San Antonio.
    Affected
    FTRE
    Transmission
    Acquiring early-phase bioanalytical capacity directly increases FTRE high-margin trial capacity and specialized pharmacology service revenue.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    FTREinorganic clinical capacity expansion lifting lab services backlogUp1-4wAcquiring Early Phase Services division for approximately $45 million.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month